Log in to save to my catalogue

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic...

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2581966506

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

About this item

Full title

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2021-10, Vol.27 (10), p.1744-1751

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- an...

Alternative Titles

Full title

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2581966506

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2581966506

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-021-01469-5

How to access this item